Ho Sang Moon Selected Research

2- ethoxy- 3- (4- (3- methyl- 5- (4- (3- methylisoxazol- 5- yl)phenyl)thiophen- 2- ylmethoxy)phenyl)propionic acid

1/2011

PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ho Sang Moon Research Topics

Disease

3	Insulin Resistance 01/2011 - 10/2008
1	Neoplasms (Cancer) 01/2021
1	Hyperglycemia 01/2011
1	Hepatocellular Carcinoma (Hepatoma) 10/2008
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 06/2007
1	Brain Ischemia (Cerebral Ischemia) 06/2007
1	Brain Injuries (Brain Injury) 06/2007
1	Ischemia 06/2007

Drug/Important Bio-Agent (IBA)

3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2011 - 10/2008
1	abemaciclibIBA 01/2021
1	dacomitinibIBA 01/2021
1	cediranib (AZD2171)IBA 01/2021
1	infigratinibIBA 01/2021
1	AlginatesIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	2- ethoxy- 3- (4- (3- methyl- 5- (4- (3- methylisoxazol- 5- yl)phenyl)thiophen- 2- ylmethoxy)phenyl)propionic acidIBA 01/2011
1	PPAR gammaIBA 05/2009
1	LipidsIBA 10/2008
1	Insulin (Novolin)FDA Link 10/2008
1	(3- (4- (2(4- (4chloro- phenyl)- 3,6- dihydro- 2H- pyridin- 1- yl)- ethoxy)- phenyl)- (2S)- ethoxy- propionic acid)IBA 10/2008
1	PPAR alphaIBA 10/2008
1	Glucose (Dextrose)FDA LinkGeneric 10/2008
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 06/2007
1	N-Methylaspartate (NMDA)IBA 06/2007
1	2- hydroxy- 5- (2,3,5,6- tetrafluoro- 4- trifluoromethyl- benzylamino)benzoic acidIBA 06/2007
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 06/2007
1	AntioxidantsIBA 06/2007
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 06/2007

Therapy/Procedure

1	Therapeutics 06/2007